Lymphoma

The weeks and days leading up to transplant, the anticipation and reality

Carl Harrington, president of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), explains the importance of Imbruvica's approval for the rare disease.

Ibrutinib becomes the first drug specifically approved for Waldenstrom's macroglobulinemia (WM), two months ahead of expectations.

Researchers gathered at the annual meeting of the American Society of Hematology to learn about survivorship issues and the late effects their patients encounter years, even decades, after therapy.

Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.

An early study in patients with Hodgkin lymphoma that had progressed on several lines of treatment found that the immunotherapy Keytruda (pembrolizumab) elicited a remarkable response.

Despite the lack of data to justify them, periodic surveillance PET scans during remission are performed frequently.

The CAR T-cell therapy JCAR015 received breakthrough therapy designation as a treatment for patients with relapsed or refractory B-cell ALL.

For patients with B-cell lymphomas, new treatments are providing more options.

Xalkori improves survival in patients with ALK-positive lymphoma.

Goals and milestone recognitions may help children with cancer get through treatment a little easier.

Long-term and late effects from toxic regimens from childhood cancer treatments include heart damage, lung problems and infertility.

Pediatric cancer treatment has come a long way, but health problems persist in survivorship.

A recent report notes that certain health issues observed in young adult survivors are typically seen in much older individuals.

Updates from the annual meeting of the American Society of Hematology.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Cancer research updates from the San Antonio Breast Cancer Symposium and American Society of Hematology.

Childhood and young adult cancer survivors need fertility preservation information, but are they getting it from their oncologists?

When it comes to treating childhood Hodgkin lymphoma patients, less radiation might be better

A kid can bring out the best in people.

Creating Hope for Childhood Cancer

A new drug regimen that combines Treanda (bendamustine) and Rituxan (rituximab) has been shown to more than double progression-free survival time.

Minimizing and preventing late effects of stem cell transplantation.

GA101 could be the next step for patients who relapse on Rituxan (rituximab), a current standard of therapy.

Patients who are not suffering from symptoms of nonbulky follicular lymphoma are better off waiting until symptoms occur before beginning chemotherapy instead of undergoing maintenance Rituxan.

With the approval of Adcetris (brentuximab vedotin) for relapsed Hodgkin lymphoma, researchers are now examining whether the drug will help newly diagnosed patients.

The latest advancements in the treatment of Hodgkin lymphoma.

Research updates from the annual San Antonio Breast Cancer Symposium and American Society of Hematology.

Researchers are looking for genetic variations to determine which patients have an increased risk for a second cancer and should receive different treatments.